Shares of Coherus BioSciences Inc. (NASDAQ:CHRS) were down 1.8% on Tuesday . The company traded as low as $29.53 and last traded at $29.66, with a volume of 213,303 shares trading hands. The stock had previously closed at $30.21.

A number of analysts recently weighed in on CHRS shares. Zacks Investment Research downgraded shares of Coherus BioSciences from a “hold” rating to a “sell” rating in a research report on Monday, August 15th. Barclays PLC reiterated a “buy” rating and issued a $46.00 price target on shares of Coherus BioSciences in a research report on Thursday, August 11th. Finally, Citigroup Inc. started coverage on shares of Coherus BioSciences in a research report on Wednesday, July 27th. They issued a “buy” rating and a $36.00 price target on the stock. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. Coherus BioSciences presently has a consensus rating of “Buy” and an average price target of $32.60.

The company has a 50 day moving average of $25.97 and a 200 day moving average of $20.12. The company’s market cap is $1.26 billion.

Coherus BioSciences (NASDAQ:CHRS) last released its earnings results on Tuesday, August 9th. The company reported ($1.72) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.32) by $0.40. The business earned $14.07 million during the quarter, compared to analysts’ expectations of $6.87 million. Analysts anticipate that Coherus BioSciences Inc. will post ($6.19) earnings per share for the current fiscal year.

In other news, insider Peter K. Watler sold 3,991 shares of the business’s stock in a transaction dated Thursday, July 21st. The stock was sold at an average price of $26.13, for a total transaction of $104,284.83. Following the sale, the insider now directly owns 3,991 shares in the company, valued at $104,284.83. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Peter K. Watler sold 43,495 shares of the business’s stock in a transaction dated Monday, July 11th. The stock was sold at an average price of $20.02, for a total value of $870,769.90. The disclosure for this sale can be found here.

An institutional investor recently raised its position in Coherus BioSciences stock. Schwab Charles Investment Management Inc. boosted its stake in Coherus BioSciences Inc. (NASDAQ:CHRS) by 1.7% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 50,108 shares of the company’s stock after buying an additional 845 shares during the period. Schwab Charles Investment Management Inc. owned about 0.13% of Coherus BioSciences worth $1,151,000 at the end of the most recent reporting period.

Coherus BioSciences, Inc is a late-stage clinical biologics platform company. The Company is focused on the global biosimilar market. The Company operates through developing and commercializing biosimilar products segment. Its business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta), in late clinical-stage, and bevacizumab (Avastin), in preclinical-stage; Immunology (Anti-TNF) biosimilar candidates, etanercept (Enbrel) and adalimumab (Humira), which are both in late clinical-stage; Ophthalmology biosimilar candidate ranibizumab (Lucentis) in preclinical stage, and Multiple sclerosis small molecule therapeutic candidate, CHS-131 (formerly INT-131), in Phase II proof-of-concept trial.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.